Recruiting OBSERVATIONAL NCT04964310

Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study (PAIN)

Pharmacogenomics of APAP Induced DILI in Chinese Population.

Sponsor: Beijing Genomics Institute

Conditions Acetaminophen China Drug-Induced Liver Injury Pharmacogenetics

Updated 5 times since 2021 Last updated: Feb 24, 2025 Started: Aug 31, 2020 Primary completion: Dec 31, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Acetaminophen and China and is currently actively recruiting participants. Beijing Genomics Institute leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Mar 2025 — Present [monthly]

Recruiting
Sep 2024 — Mar 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Dec 2021 — Jul 2024 [monthly]

Recruiting
Sep 2021 — Dec 2021 [monthly]

Recruiting

First recorded

Aug 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Genomics Institute
Nanjing Medical University
The First Affiliated Hospital with Nanjing Medical University
University of Colorado, Denver

Data source: The First Affiliated Hospital with Nanjing Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanjing, China